Regulation of CD8+ T Cell Homeostatis by IL-4

IL-4 对 CD8 T 细胞稳态的调节

基本信息

  • 批准号:
    8204960
  • 负责人:
  • 金额:
    $ 38.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-01-15 至 2013-12-31
  • 项目状态:
    已结题

项目摘要

This proposal will study IL-4 regulation of T cell homeostasis and immunity. It will investigate the four part hypothesis that: 1) IL-4 stimulates CD8+ T cells to proliferate; 2) IL-4 also stimulates non-T cells to differentiate into regulatory cells that suppress activated CD8+ T cells; 3) differences in the kinetics of these two processes cause IL-4 to first enhance, then suppress CD8+ T cell responses; and 4) these phenomena are important in CD8+ T cell homeostasis in health and disease. This hypothesis is based on in vivo mouse studies that demonstrate that: 1) IL-4 is essential for normal CD8+ T cell homeostasis, especially memory CD8+ T cell homeostasis; and 2) physiological concentrations of IL-4 acutely induce CD8+ T cells to proliferate through a partially Stat6-dependent process but more slowly decrease CD8+ T cell responses and cell number through an entirely Stat6-dependent process. Suppression is associated with the appearance of an enlarged, activated population of CD11b+Ly6Ghi neutrophils, which have been implicated by other investigators in the inactivation and killing of activated CD8+ T cells. Our hypothesis is addressed in 3 specific aims. The first evaluates signaling requirements for IL-4 stimulation of T cell activation and survival. It will determine the importance of IL-4 activation of Stat6, Stat5, and PI-3K for the mitogenic and anti-apoptotic effects of IL-4. It will also investigate why both IL-4 and IL-15 are required to maintain memory CD8+ T cells. The second aim addresses IL-4-activation of regulatory cells. It will identify and characterize the spleen cells activated by IL-4 to suppress and kill activated CD8+ T cells; determine the dose of IL-4 required to activate these regulatory cells; identify the signaling pathways important for their activation; identify the mechanism(s) by which they kill activated T cells, and evaluate their importance in a mouse model in which IL-4 suppresses cytotoxic graft vs. host disease (GVHD). The third aim will evaluate the effects of endogenously-produced IL-4 and a related cytokine, IL-13, on CD8+ T cell homeostasis in health and disease. To allow evaluation of the generalizability of our results, this aim will examine the effects of IL-4 and IL-13 on T cell homeostatsis in mouse models of two inflammatory disorders: allergic airway inflammation (asthma) and Omann's syndrome; and mouse models of three infectious diseases: schistosomiasis, malaria, and lymphocytic choriomeningitis virus (LCMV) infection. Each of these models has been chosen because it can provide some unique information about IL-4 regulation of T cell homeostasis and immunity and because it also can shed light on the disease-relevance of IL-4 regulation. Proposed experiments will be performed in vivo and use transgenic mice, recombinant cytokines, monoclonal antibodies, cell transfer systems, CFSE labeling, BrdU incorporation, assays of in vivo cytokine production and flow cytometry to test our hypothesis. Results of these studies should identify the circumstances in which IL-4 promotes or regulates CD8+ T cell responses and provide a guide to the potential uses of IL-4 and IL-4 antagonists for amplifying or suppressing adaptive or maladaptive CD8+ T cell responses in humans.
这项建议将研究IL-4对T细胞稳态和免疫的调节。它将对四个部分进行调查 假设:1)IL-4刺激CD8+T细胞增殖;2)IL-4也刺激非T细胞分化 转化为抑制激活的CD8+T细胞的调节细胞;3)这两个过程的动力学差异 导致IL-4首先增强,然后抑制CD8+T细胞反应;4)这些现象在 CD8+T细胞在健康和疾病中的动态平衡这一假设是基于对小鼠的活体研究 提示:1)IL-4对正常的CD8+T细胞,尤其是记忆性CD8+T细胞的稳态是必不可少的 2)生理浓度的IL-4可显著诱导CD8+T细胞通过 部分依赖Stat6的过程,但更缓慢地降低CD8+T细胞反应和细胞数量 这是一个完全依赖于Stat6的过程。抑制与放大的、激活的 CD11b+Ly6Ghi中性粒细胞群体,已被其他研究人员发现与失活有关 并杀伤活化的CD8+T细胞。我们的假设有三个具体目标。第一个评估 IL-4刺激T细胞活化和存活所需的信号。它将决定 IL-4激活STAT6、STAT5和PI-3K对IL-4促有丝分裂和抗凋亡作用的影响它还将 研究为什么需要IL-4和IL-15来维持记忆中的CD8+T细胞。第二个目标是解决 IL-4-调节细胞的激活。它将鉴定和鉴定由IL-4激活的脾细胞以抑制 并杀死激活的CD8+T细胞;确定激活这些调节细胞所需的IL-4剂量;识别 对它们的激活至关重要的信号通路;确定它们杀死活化T细胞的机制(S) 细胞,并在IL-4抑制细胞毒性移植物对宿主疾病的小鼠模型中评估它们的重要性 (GVHD)。第三个目标将评估内源性产生的IL-4和相关细胞因子IL-13的效果, 健康与疾病对CD8+T细胞动态平衡的影响为了能够评估我们结果的概括性,这 目的探讨IL-4和IL-13对两种炎症模型小鼠T细胞稳态的影响。 疾病:过敏性呼吸道炎症(哮喘)和Omann综合征;以及三种疾病的小鼠模型 传染病:血吸虫病、疟疾和淋巴细胞性脉络膜脑膜炎病毒感染。每个人 这些模型之所以被选中,是因为它可以提供一些关于IL-4调节T细胞的独特信息 细胞动态平衡和免疫,因为它还可以阐明IL-4调节与疾病的相关性。 拟议的实验将在体内进行,并使用转基因小鼠、重组细胞因子、单克隆 抗体,细胞转移系统,CFSE标记,BrdU掺入,体内细胞因子产生和检测 用流式细胞仪来验证我们的假设。这些研究的结果应该确定IL-4在什么情况下 促进或调节CD8+T细胞反应,并为IL-4和IL-4的潜在用途提供指南 增强或抑制人类适应性或非适应性CD8+T细胞反应的拮抗剂。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation.
  • DOI:
    10.1126/science.1204351
  • 发表时间:
    2011-06-10
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jenkins SJ;Ruckerl D;Cook PC;Jones LH;Finkelman FD;van Rooijen N;MacDonald AS;Allen JE
  • 通讯作者:
    Allen JE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FRED Douglass FINKELMAN其他文献

FRED Douglass FINKELMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FRED Douglass FINKELMAN', 18)}}的其他基金

Rapid, safe suppression of IgE-mediated disease with monovalent anti-ceRIa mAb
使用单价抗 ceRIa mAb 快速、安全地抑制 IgE 介导的疾病
  • 批准号:
    10468082
  • 财政年份:
    2019
  • 资助金额:
    $ 38.22万
  • 项目类别:
Rapid, safe suppression of IgE-mediated disease with monovalent anti-ceRIa mAb
使用单价抗 ceRIa mAb 快速、安全地抑制 IgE 介导的疾病
  • 批准号:
    10213608
  • 财政年份:
    2019
  • 资助金额:
    $ 38.22万
  • 项目类别:
Rapid, safe suppression of IgE-mediated disease with monovalent anti-ceRIa mAb
使用单价抗 ceRIa mAb 快速、安全地抑制 IgE 介导的疾病
  • 批准号:
    10645062
  • 财政年份:
    2019
  • 资助金额:
    $ 38.22万
  • 项目类别:
Wimpy antibody isotypes protect against antibody-mediated disease
Wimpy 抗体同种型可预防抗体介导的疾病
  • 批准号:
    9287287
  • 财政年份:
    2017
  • 资助金额:
    $ 38.22万
  • 项目类别:
Suppression of IgE-Mediated Disease by Polyclonal Rapid Desensitization
通过多克隆快速脱敏抑制 IgE 介导的疾病
  • 批准号:
    9098577
  • 财政年份:
    2014
  • 资助金额:
    $ 38.22万
  • 项目类别:
Suppression of IgE-Mediated Disease by Polyclonal Rapid Desensitization
通过多克隆快速脱敏抑制 IgE 介导的疾病
  • 批准号:
    8889194
  • 财政年份:
    2014
  • 资助金额:
    $ 38.22万
  • 项目类别:
Suppression of established IgE-mediated disease
抑制已确定的 IgE 介导的疾病
  • 批准号:
    8601247
  • 财政年份:
    2012
  • 资助金额:
    $ 38.22万
  • 项目类别:
Suppression of established IgE-mediated disease
抑制已确定的 IgE 介导的疾病
  • 批准号:
    8795681
  • 财政年份:
    2012
  • 资助金额:
    $ 38.22万
  • 项目类别:
Suppression of established IgE-mediated disease
抑制已确定的 IgE 介导的疾病
  • 批准号:
    8239859
  • 财政年份:
    2012
  • 资助金额:
    $ 38.22万
  • 项目类别:
Suppression of established IgE-mediated disease
抑制已确定的 IgE 介导的疾病
  • 批准号:
    8698290
  • 财政年份:
    2012
  • 资助金额:
    $ 38.22万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.22万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了